Newsfilter article unlocker

Hello and welcome everyone joining today's Miravai Life Sciences Q1 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Deb Hart, Head of Investor Relations. Please go ahead. Good afternoon, everyone. Thanks for joining us for our first quarter 2026 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.moravai.com. As you can see from the agenda on slide two, our CEO, Vern Brust, will provide a business update and our CFO, Raj Althapota, will review our financial results. Dr. Chen Feng Zhao, our Chief Scientific Officer, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. It's possible that actual results could differ from expectations. We refer you to slide 3 for details on forward- looking statements and our use of non-GAAP financial measures. The press release provides reconciliations to the most directly comparable GAAP measures and we also post reconciling schedules to our investor website. Please also refer to Maravai's SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I'll turn the call over to Bernd. Good afternoon, and thank you for joining us. We are very pleased with our first quarter performance, which represents a strong start to 2026 and builds on the momentum we exited with last year. The quarter results reflect solid execution across the business and reinforce our confidence in the trajectory we outlined on our call in February. Turning to slide five, we delivered total Q1 revenue of $65.8 million. That's 41% year-over-year growth and 10% year over year growth in our base business when you exclude COVID-related clean cap revenue. This performance was driven by improved TriLink demand, steady contribution from Cygnus and continued progress against our strategic priorities. TriLink revenue grew 65% yearover year with the base business growth of 15% supported by strong demand in both GMP and Discovery consumables. At Cygnus, revenue grew a little more than 1% year over year. We saw solid underlying momentum with high single digit growth in North America and low single digit growth in EMEA, reinforcing our confidence in the positioning of the business. This was partially offset by lower contribution from China due to distributor ordering timing. From a profitability standpoint, we delivered adjusted gross margin of 65.3% and adjusted EBITDA of $20.3 million. These results reflect the benefit of higher revenue, favorable product and customer mix, and the cost disciplines we have implemented across the organization. We also generated $4.2 million of positive free cash flow in the quarter, which is the first time the company has been cash flow positive since Q3 of 2024. We see this as another clear indication that the structural improvements we have made are taking hold. Given our strong start to the year and improved visibility into the balance of 2026, we are increasing the range for our full year revenue expectations and substantially raising our EBITDA guidance. Raj will walk through that in more detail shortly. Now let's turn to slide 6 for an update on our performance against our three strategic pillars. Commercial execution, operational excellence, and of course innovation. Starting with commercial execution, we are seeing strong momentum across the business. Our increased focus on customer engagement is translating into better forecasting, improved visibility, and stronger order conversion. We are securing more annual and multi-quarter purchase orders, which is improving the stability and predictability of our revenue base. This is a meaningful shift from where we were a year ago and reflects the effectiveness of the changes we have made in our commercial go-to-market approach. That said, our business has a disproportionate number of large orders that can result in quarter-over-quarter performance variation. Large orders tend to align with customer program progression, and as a result, revenue can vary between periods. What gives us confidence is not the timing of any single order, but the strength and continued expansion of the underlying opportunity funnel. Within TriLink, our portfolio now spans enabling technologies such as CleanCap and Matel, along with custom and catalog mRNA, enzymes, oligonucleotides including guide RNAs, and a broad range of nucleotide chemistries including NTPs. This breadth allows us to participate more deeply across the mRNA and gene therapy workflows. We also recently launched all-in-one IVT kits which simplify the production of capped RNA and provide early-stage researchers with easier access to our platform. At TriLink, our model continues to work as intended. We establish relationships early in discovery, embed our technologies in customer workflows, and then grow with those programs as they advance into GMP. Mentions of TriLink technologies in scientific publications remain strong, underscoring their role in customer workloads, which we view as an important leading indicator of future demand. A key highlight in the quarter is the continued adoption of Mottail. We now have more than 70 customers using this technology across both large pharmaceutical companies and emerging biotechs. We are seeing growth in new customers, repeat orders, and increasing use across multiple applications. We also see continued strength in our GMP funnel, with GMP customers expected to grow 22% in 2026 representing nine existing REO customers transitioning to GMP customers two of which we have already converted this year many of these programs are progressing into later clinical stages which supports the durability of the demand as a long-term GMP supplier at Cygnus we saw growth from our newer DNA quantification and extraction kits as well as from our mock-free product offering. These product lines extend us beyond our traditional HCP franchise into adjacent applications. While still early, we are encouraged by the traction we are seeing as customers look for high-quality analytical tools across their development and manufacturing workflows. And finally, at Cygnus our kits continue to play a critical role in the market with a 100% attach rate, supporting the safety testing of all 29 of the 29 FDA or EMA-approved CAR-T cell and gene therapies. Now turning to operational excellence. This remains a core focus and a key driver of our improved financial performance. The restructuring actions implemented last year continue to deliver results, and we now expect to achieve more than $65 million in annual EBITDA savings, These savings span labor, facilities,